Pfizer Inc. (NYSE:PFE) is Ropes Wealth Advisors LLC’s 6th Largest Position

Ropes Wealth Advisors LLC trimmed its position in Pfizer Inc. (NYSE:PFEGet Rating) by 3.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 192,838 shares of the biopharmaceutical company’s stock after selling 7,829 shares during the quarter. Pfizer comprises 2.0% of Ropes Wealth Advisors LLC’s holdings, making the stock its 6th largest position. Ropes Wealth Advisors LLC’s holdings in Pfizer were worth $11,387,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in PFE. Bank OZK lifted its holdings in shares of Pfizer by 0.3% in the 4th quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company’s stock valued at $4,067,000 after purchasing an additional 195 shares during the last quarter. TimeScale Financial Inc. lifted its holdings in shares of Pfizer by 2.9% in the 4th quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company’s stock valued at $412,000 after purchasing an additional 196 shares during the last quarter. Bath Savings Trust Co lifted its holdings in shares of Pfizer by 0.5% in the 4th quarter. Bath Savings Trust Co now owns 39,684 shares of the biopharmaceutical company’s stock valued at $2,344,000 after purchasing an additional 200 shares during the last quarter. Fruth Investment Management lifted its holdings in shares of Pfizer by 0.7% in the 4th quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company’s stock valued at $1,730,000 after purchasing an additional 200 shares during the last quarter. Finally, Cortland Associates Inc. MO lifted its holdings in shares of Pfizer by 2.6% in the 4th quarter. Cortland Associates Inc. MO now owns 7,897 shares of the biopharmaceutical company’s stock valued at $466,000 after purchasing an additional 201 shares during the last quarter. Hedge funds and other institutional investors own 66.50% of the company’s stock.

Several research firms have commented on PFE. Morgan Stanley began coverage on Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 price objective for the company. Citigroup upped their price objective on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research note on Tuesday, April 5th. Wells Fargo & Company reduced their price objective on Pfizer from $60.00 to $55.00 in a research note on Wednesday, May 4th. JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a research note on Tuesday, May 3rd. Finally, The Goldman Sachs Group set a $51.00 price objective on Pfizer in a research note on Wednesday, May 4th. Eleven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Buy” and an average target price of $57.05.

Shares of PFE traded down $0.47 on Friday, reaching $49.92. The stock had a trading volume of 22,423,685 shares, compared to its average volume of 24,886,970. The firm has a market capitalization of $281.94 billion, a PE ratio of 11.45, a PEG ratio of 0.59 and a beta of 0.76. The company has a quick ratio of 1.19, a current ratio of 1.40 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average of $51.27 and a 200 day moving average of $51.84. Pfizer Inc. has a twelve month low of $38.47 and a twelve month high of $61.71.

Pfizer (NYSE:PFEGet Rating) last released its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, missing analysts’ consensus estimates of $1.80 by ($0.18). The firm had revenue of $25.66 billion during the quarter, compared to analyst estimates of $24.73 billion. Pfizer had a return on equity of 39.33% and a net margin of 26.97%. The business’s revenue was up 76.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.93 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 6.69 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Friday, May 13th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date is Thursday, May 12th. Pfizer’s dividend payout ratio (DPR) is presently 36.70%.

In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the sale, the executive vice president now owns 38,146 shares in the company, valued at approximately $1,907,300. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is currently owned by corporate insiders.

About Pfizer (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.